ZIRGAN Drug Patent Profile
✉ Email this page to a colleague
When do Zirgan patents expire, and when can generic versions of Zirgan launch?
Zirgan is a drug marketed by Bausch And Lomb and is included in one NDA.
The generic ingredient in ZIRGAN is ganciclovir. There are twenty-seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the ganciclovir profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ZIRGAN?
- What are the global sales for ZIRGAN?
- What is Average Wholesale Price for ZIRGAN?
Summary for ZIRGAN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 151 |
| Clinical Trials: | 2 |
| Drug Prices: | Drug price information for ZIRGAN |
| What excipients (inactive ingredients) are in ZIRGAN? | ZIRGAN excipients list |
| DailyMed Link: | ZIRGAN at DailyMed |
Recent Clinical Trials for ZIRGAN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Northwestern University | Phase 2 |
| Bausch & Lomb Incorporated | Phase 2 |
| Lifelong Vision Foundation | Phase 4 |
Pharmacology for ZIRGAN
| Drug Class | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor Nucleoside Analog Antiviral |
| Mechanism of Action | DNA Polymerase Inhibitors |
US Patents and Regulatory Information for ZIRGAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch And Lomb | ZIRGAN | ganciclovir | GEL;OPHTHALMIC | 022211-001 | Sep 15, 2009 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for ZIRGAN
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Dr. Gerhard Mann, Chem.-Pharm. Fabrik GmbH.. | Vitrasert Implant | ganciclovir | EMEA/H/C/000120 The Vitrasert implant is indicated for the local treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) (See 4.4. Special warnings and special precautions for use). |
Withdrawn | no | no | no | 1997-03-18 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
